Amplia Therapeutics (ATX) Price & Analysis

Compare

23 Followers

ATX Stock Chart & Stats

AU$0.14

<AU$0.01(2.33%)

At close: Jan 09 4:00 PM EST

AU$0.14

<AU$0.01(2.33%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.43

Previous CloseN/A

Volume274.48K

Average Volume (3M)525.22K

Market Cap

AU$62.85M

Enterprise ValueAU$32.79M

Total Cash (Recent Filing)AU$29.16M

Total Debt (Recent Filing)AU$381.42K

Price to Earnings (P/E)―

Beta0.75

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding513,071,660

10 Day Avg. Volume444,673

30 Day Avg. Volume525,217

Financial Highlights & Ratios

PEG Ratio0.42

Price to Book (P/B)1.02

Price to Sales (P/S)5.68

P/FCF Ratio-3.12

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Healthy Equity BaseA low debt-to-equity ratio and healthy equity ratio provide a durable financial buffer for a development-stage biotech. This conservative leverage profile reduces default risk, supports capital allocation for R&D or partnering, and preserves strategic optionality for 2-6 month funding or collaboration decisions.

Very Strong Gross MarginsConsistently >90% gross margins indicate a highly scalable, low incremental-cost model around the company's core R&D/IP. When paired with successful clinical progress or licensing, such margins can translate into high operating leverage, attractive partner economics, and sustainable profitability once revenues scale.

Focused Clinical-stage Oncology PipelineA clear strategic focus on FAK inhibition and a lead candidate (narmafotinib) in combination regimens targets high-unmet-need solid tumors. This concentrated scientific thesis enhances R&D efficiency, makes the company an attractive partner or acquisition target, and aligns with structural oncology demand for targeted combination therapies.

Bears Say

Negative Operating And Free Cash FlowSustained negative operating and free cash flows create a structural funding need typical of clinical-stage biotechs. Continued cash burn increases reliance on equity raises, partnerships, or milestone-based funding, which can dilute shareholders or delay trials if financing terms are unfavorable within the next several quarters.

Ongoing Net Losses And Negative MarginsPersistent negative net, EBIT and EBITDA margins reflect heavy R&D expenditures and absence of commercial revenues. Structural unprofitability limits reinvestment capacity and increases the necessity of external funding or strategic deals to advance clinical programs toward value-accretive milestones.

Extremely Limited Internal ResourcesA one-person headcount signals constrained internal capability to manage multiple trials, regulatory workstreams, or commercialization planning. Heavy reliance on CROs and partners increases execution risk, can slow timelines, and may raise long-term operating costs or coordination complexity for clinical programs.

Amplia Therapeutics News

Amplia Expands U.S. Footprint With New Sites for Pancreatic Cancer Trial

Amplia Therapeutics ( ($AU:ATX) ) has issued an announcement. Amplia Therapeutics has opened two new U.S. clinical sites...

9d ago

Amplia Secures Phase 3-Ready Supply with First Large-Scale Narmafotinib Manufacture

Amplia Therapeutics ( ($AU:ATX) ) has provided an announcement. Amplia Therapeutics has completed the first large-scale, GMP-compliant manufacture...

29d ago

Amplia Showcases Promising Pancreatic Cancer Data for Narmafotinib at ASCO GI

The latest update is out from Amplia Therapeutics ( ($AU:ATX) ). Amplia Therapeutics has reported updated interim data...

1M ago

Amplia Deepens Next & Bio Collaboration to Test Narmafotinib–kRAS Combo in Pancreatic Cancer

Amplia Therapeutics ( ($AU:ATX) ) has shared an announcement. Amplia Therapeutics has entered a second phase of its...

2M ago

Amplia Therapeutics Reports Positive ACCENT Trial Results for Pancreatic Cancer

The latest announcement is out from Amplia Therapeutics ( ($AU:ATX) ). Amplia Therapeutics announced a positive development in...

2M ago

Amplia Therapeutics Reports Promising Trial Results for Pancreatic Cancer Drug

An announcement from Amplia Therapeutics ( ($AU:ATX) ) is now available. Amplia Therapeutics has announced its financial report...

3M ago

Amplia Therapeutics Receives FDA Support for Pancreatic Cancer Trial

The latest update is out from Amplia Therapeutics ( ($AU:ATX) ). Amplia Therapeutics has received positive feedback from...

3M ago

Amplia Therapeutics Issues New Equity Securities

The latest update is out from Amplia Therapeutics ( ($AU:ATX) ). Amplia Therapeutics Limited has announced the issuance...

3M ago

Amplia Therapeutics Expands U.S. Market Presence with OTCQB Listing

Amplia Therapeutics ( ($AU:ATX) ) has shared an announcement. Amplia Therapeutics has commenced trading on the U.S. OTCQB...

4M ago

Amplia Therapeutics Advances Narmafotinib Trials with Promising Results

An announcement from Amplia Therapeutics ( ($AU:ATX) ) is now available. Amplia Therapeutics has reported significant progress in...

4M ago

ATX FAQ

What was Amplia Therapeutics Ltd.’s price range in the past 12 months?

Amplia Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.42 in the past 12 months.

What is Amplia Therapeutics Ltd.’s market cap?

Amplia Therapeutics Ltd.’s market cap is AU$62.85M.

When is Amplia Therapeutics Ltd.’s upcoming earnings report date?

Amplia Therapeutics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 101 days.

How were Amplia Therapeutics Ltd.’s earnings last quarter?

Amplia Therapeutics Ltd. released its earnings results on Nov 27, 2025. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.

Is Amplia Therapeutics Ltd. overvalued?

According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Amplia Therapeutics Ltd. pay dividends?

Amplia Therapeutics Ltd. does not currently pay dividends.

What is Amplia Therapeutics Ltd.’s EPS estimate?

Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Amplia Therapeutics Ltd. have?

Amplia Therapeutics Ltd. has 513,071,660 shares outstanding.

What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?

Amplia Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.

Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?

Currently, no hedge funds are holding shares in AU:ATX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Amplia Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-27.39%

Trailing 12-Months

Asset Growth

199.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Amplia Therapeutics Ltd.

Amplia Therapeutics (ATX) is a biotechnology company focused on developing innovative therapies for the treatment of fibrotic diseases and cancer. The company specializes in the discovery and development of small molecule drugs that target the underlying biological processes driving these conditions. Amplia's core products include its lead drug candidate, which is designed to inhibit specific pathways involved in fibrosis, thereby offering potential benefits for patients suffering from these debilitating diseases.